Charles River Laboratories (CRL) Tops Q3 EPS by 9c, Offers Guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $280.76 -2.68%
EPS Growth %: +21.8%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +21.8%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.63, $0.09 better than the analyst estimate of $2.54. Revenue for the quarter came in at $989.2 million versus the consensus estimate of $974.65 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $10.80-$10.95, versus the consensus of $10.80.
- Revenue growth, reported 10.0% – 11.0%
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- Braze stock tumbles 10% on weak third quarter EPS guidance
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
